Last reviewed · How we verify
Triple combination formula
A triple combination formula that combines three active pharmaceutical ingredients to produce synergistic therapeutic effects.
At a glance
| Generic name | Triple combination formula |
|---|---|
| Also known as | Maleate Timolol 0.5%, Brimonidine Tartarate 0.2%, Bimatoprost 0.03%, modified Kligman formula |
| Sponsor | Federal University of São Paulo |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Without specification of the exact three components, the mechanism cannot be precisely defined. Triple combination formulas typically work by targeting multiple pathways or mechanisms simultaneously to enhance efficacy. The Federal University of São Paulo has developed this marketed formulation, likely for a specific therapeutic indication.
Approved indications
Common side effects
Key clinical trials
- ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (PHASE1, PHASE2)
- Trial Comparing Cataract Surgery With Triple-DMEK in Patients With Cataract and Fuchs Endothelial Corneal Dystrophy (NA)
- Triplenex (triple Fixed Combination) Use Evaluation in Patients with Glaucoma (PHASE4)
- Oral Isotretinoin in Melasma a Randomized Controlled Trial (PHASE1)
- Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Triple combination formula CI brief — competitive landscape report
- Triple combination formula updates RSS · CI watch RSS
- Federal University of São Paulo portfolio CI